Abstract 1372 Targeting USP24 induced ferroptosis and mitochondrial dysfunction in drug-resistant lung cancer

Lung cancer not only possesses the highest global mortality rate among all cancers, but also affects over 10% of the population. Consequently, the number of drugs for treating lung cancer is steadily increasing. However, currently approved drugs, while initially effective, often face the challenge of relapse over time. This recurrence is attributed to the development of drug resistance in cancer cells, leading to a diminished therapeutic effect. Therefore, there is an unmet medical need to develop drugs that can re-sensitize resistant cancer cells, promoting cancer cell death.